NASDAQ : DWTX
Dogwood Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.23 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 41.81M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 43.51M |
| Enterprise Value | 34.03M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 33.99M |
| Shares Outstanding | 33.99M |
| Shares Change (YoY) | +1,355.57% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 2.27% |
| Float | 1.71M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.63 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.89 |
| Quick Ratio | 3.39 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -47.77% |
| Return on Assets (ROA) | -20.83% |
| Return on Invested Capital (ROIC) | -24.41% |
| Return on Capital Employed (ROCE) | -38.02% |
| Weighted Average Cost of Capital (WACC) | 14.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.51M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -2.45M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.94 |
| 52-Week Price Change | -79.25% |
| 50-Day Moving Average | 1.68 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 44.06 |
| Average Volume (20 Days) | 74,392 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 62,406 |
| Short Previous Month | 38,895 |
| Short % of Shares Out | 0.18% |
| Short % of Float | 3.65% |
| Short Ratio (days to cover) | 0.90 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.53M |
| Pretax Income | -38.49M |
| Net Income | -36.04M |
| EBITDA | -29.56M |
| EBIT | -29.53M |
| Earnings Per Share (EPS) | -$1.71 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.61M |
| Total Debt | 127,208 |
| Net Cash | 9.48M |
| Net Cash Per Share | $0.28 |
| Equity (Book Value) | 68.37M |
| Book Value Per Share | 2.03 |
| Working Capital | 8.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -15.11M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | -31,183 |
| Net Borrowing | n/a |
| Free Cash Flow | -15.11M |
| FCF Per Share | -$0.44 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,355.57% |
| Shareholder Yield | -1,355.57% |
| Earnings Yield | -133.72% |
| FCF Yield | -34.72% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.00 |
| Price Target Difference | 993.75% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 9, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |